NEUROMODULATION DEVICES MARKET ANALYSIS

Neuromodulation Devices Market, by Device Type (Spinal Cord Stimulation Devices, Deep Brain Stimulation Devices, Sacral Nerve Stimulation Devices, Vagus Nerve Stimulation Devices, and Gastric Electric Stimulation Devices), by Application (Pain Management, Neurological and Movement Disorder Management, Musculoskeletal Disorder Management, Metabolism and GIT Management and Others (Incontinence Management, etc.)) by End User (Hospitals, Ambulatory Surgical Centers, Specialized Clinics, and Others (Nursing Facilities, etc.)) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) -

Published In : Jun 2023
Code : CMI3861
Pages :170
Formats :
Excel and PDF
Industry : Medical Devices

Market News

Global Neuromodulation Devices Market: Key Developments

Increasing CE mark approval of neuromodulation devices by regulatory authorities is expected to propel growth of the global neuromodulation devices market. For instance, in January, 2020, Bioness Inc., a subsidiary company of Bioventus, announced that it had received CE mark approval for StimRouter neuromodulation system for the treatment of fecal incontinence across Europe.
Increasing product approval by regulatory authorities is expected to drive the market growth over the forecast period. For instance, in August 2022, Abbott, a medical technology company, announced that it had received U.S. Food and Drug Adminstration (FDA) approved Proclaim Plus Spinal Cord Stimulation (SCS) system featuring FlexBurst360 therapy. The next generation of Abbott’s proprietary BurstDR stimulation, FlexBurst360 therapy offers pain coverage across up to six areas of the trunk and/or limbs and enables programming that can be adjusted as a person’s therapeutic needs evolve

Global Neuromodulation Devices Market: Key Trends

Increasing adoption of organic strategies such as acquisition by key market players to expand its product portfolio

Increasing adoption of organic strategies, such as the acquisition, by key market players to expand its product portfolio is expected to drive the global neuromodulation devices market growth over the forecast period. For instance, in March 2021, Bioventus, a medical device company, announced that they had acquired Bioness, Inc., a neuromodulation and rehabilitation medical devices company, to expand its product portfolio. Under this acquisition, Bioventus includes the entire portfolio of Bioness products as well as its research and development pipeline and Bioness has become a wholly-owned subsidiary of Bioventus.